文献速递认知障碍与痴呆

脑龄差与标准MRI评估在主观认知下降和轻度认知障碍中的痴呆风险分层比较

Comparison of Brain Age With Standard MRI Assessment for Dementia Risk Stratification in Subjective and Mild Cognitive Impairment.
PubMed 文献 · Neurology · 2026-08-10

本研究基于阿姆斯特丹痴呆队列和SCIENCe项目,纳入799例主观认知下降(SCD)和轻度认知障碍(MCI)患者,评估脑预测年龄差(brain-PAD)对痴呆进展的预测价值。结果显示,较高的brain-PAD与痴呆进展风险增加相关(HR 1.04,95%CI 1.02-1.06),且在SCD患者中预测价值更强(HR 1.09,95%CI 1.03-1.15),并优于视觉评定量表。

要点

  • brain-PAD每增加1年,痴呆进展风险增加4%(HR 1.04)。
  • 在SCD患者中,brain-PAD预测价值更强(HR 1.09),且优于视觉评定量表。
  • brain-PAD截断值-2.6年对2-10年痴呆进展有高阴性预测值(0.91-0.99)。

核心结论

  • MRI衍生的brain-PAD可预测SCD或MCI患者进展为痴呆,尤其在SCD患者中提供超出视觉评定量表的额外预测价值。

研究设计与样本

  • 回顾性队列研究,纳入阿姆斯特丹痴呆队列和SCIENCe项目中799例SCD(412例)和MCI(387例)患者,随访至10年。

主要发现

  • 中位随访3.2年,235例(29.4%)进展为痴呆;较高brain-PAD与痴呆进展风险增加相关(HR 1.04,95%CI 1.02-1.06)。
  • brain-PAD与基线诊断存在显著交互作用(p=0.013),SCD中HR 1.09(95%CI 1.03-1.15),MCI中HR 1.01(95%CI 0.99-1.04)。
  • 在SCD中,brain-PAD改善模型拟合(χ2=10.17,p=0.003)并轻度提高区分度(C-index +0.02);在MCI中无额外价值(χ2=0.88,p=0.351)。
  • brain-PAD截断值-2.6年在2-10年随访中对应高阴性预测值(0.91-0.99)。
  • 在生物标志物亚组中,brain-PAD改善模型拟合超越淀粉样蛋白状态(χ2=6.44,p=0.018),但未提高区分度。

关键数值与推荐

  • brain-PAD与痴呆进展风险的HR为1.04(95%CI 1.02-1.06)。
  • SCD患者中brain-PAD的HR为1.09(95%CI 1.03-1.15),MCI患者中HR为1.01(95%CI 0.99-1.04)。
  • brain-PAD截断值-2.6年的阴性预测值为0.91-0.99(2-10年)。

临床怎么用

  • 在记忆门诊中,brain-PAD可辅助SCD患者的痴呆风险分层,尤其当视觉评定量表结果不明确时。
  • brain-PAD截断值-2.6年可用于识别痴呆进展低风险个体,高阴性预测值支持其排除价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Early dementia risk-stratification is crucial for timely intervention. Brain-predicted age difference (brain-PAD) derived from structural MRI reflects the gap between computer-estimated age and chronological age and has been linked to clinical progression to dementia. We evaluate whether brain-PAD has prognostic value for progression to dementia in subjective cognitive decline (SCD) and mild cognitive impairment (MCI) and whether brain-PAD provides added value beyond visual rating scales. METHODS: This retrospective cohort study included patients with SCD and MCI with up to 10-year follow-up assessments from the Amsterdam Dementia Cohort and SCIENCe project. Brain-PAD was computed from baseline MRI using 2 pretrained methods. Cox proportional hazards models assessed the association between brain-PAD and risk of progression to dementia, controlling for age, sex, Mini Mental State Examination, and visual rating scales. We tested interactions between brain-PAD and baseline diagnosis to assess stage-specific value and evaluated the added value beyond amyloid status in a biomarker-available subset. RESULTS: The study included 799 patients (SCD 412, MCI 387; 39.4% female, 63.3 ± 8.0 years). During a median follow-up of 3.2 years, 235 (29.4%) progressed to dementia. Higher brain-PAD was associated with an increased risk of progression to dementia (hazard ratio [HR] 1.04, 95% CI 1.02-1.06) and improved model fit beyond visual ratings (χ2 = 12.24, p = 0.003). Following a significant interaction between brain-PAD and baseline diagnosis (p = 0.013), stratified analyses demonstrated brain-PAD was a stronger predictor in SCD (HR 1.09, 95% CI 1.03-1.15) than in MCI (HR 1.01, 95% CI 0.99-1.04). In SCD, brain-PAD improved model fit beyond visual rating scales (χ2 = 10.17, p = 0.003) and modestly increased discrimination (C-index +0.02). A data-driven brain-PAD cutoff of -2.6 years corresponded to a high negative predictive value (0.91-0.99) over 2-10 years. Although brain-PAD improved model fit beyond amyloid status (χ2 = 6.44, p = 0.018), it did not improve discrimination. In MCI, brain-PAD provided no additional value (χ2 = 0.88, p = 0.351). DISCUSSION: MRI-derived brain-PAD predicts progression to dementia in memory clinic patients with SCD or MCI. In particular, brain-PAD provided additional predictive value to visual rating scales in patients with SCD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. De Vries S, Farkas K, Rhodius-Meester HFM, et al. Comparison of Brain Age With Standard MRI Assessment for Dementia Risk Stratification in Subjective and Mild Cognitive Impairment. Neurology. 2026. PMID: 42574695. doi:10.1212/WNL.0000000000218418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。